Based on its share price, down 75% in the last three years, it's easy to write off Moderna (NASDAQ: MRNA) as a biotech ...

Moderna (MRNA) stock falls as Goldman Sachs downgrades the COVID-19 vaccine maker to Neutral from Buy, citing a lack of ...

Are you ready for artificial intelligence (AI)-driven mRNA vaccines?

Moderna's trailing-12-month revenue is just ... And despite widespread outbreaks of respiratory syncytial virus (RSV), the recent approval of its RSV vaccine has also not moved the needle much.

Moderna works on mRNA vaccines, which use synthetic code to instruct the body to make specific proteins to fight a disease. The company is currently working on vaccines for RSV and the seasonal ...

Share prices of Moderna (NASDAQ: MRNA) plummeted 58% in 2024, ranking among the worst performers in the S&P 500 index. The ...

Demand for its COVID vaccine has been waning since the pandemic, while adoption of its RSV shot - its second approved product- has been slower than expected, forcing Moderna to cut costs.

"We remain focused on our three strategic priorities: driving sales growth, delivering up to 10 product approvals over the next three years, and reducing costs across our business." MRNA Stock Is in a ...